Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026

Syndax Pharmaceuticals (SNDX) will report third quarter 2026 financial results and provide a business update on November 2, 2026.

Rhea-AI Summary

Syndax Pharmaceuticals (SNDX) will report third quarter 2026 financial results and provide a business update on November 2, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET that day. The webcast and accompanying slides will be accessible through the company's investor website. A replay will be available approximately 24 hours after the call and remain available for 90 days following the call.

Key Figures

Financial results announcement date: November 2, 2026

Financial results announcement date

November 2, 2026

Third quarter 2026 results and business update

Key Terms

fda-approved, menin inhibitor, monoclonal antibody, csf-1 receptor

4 terms

fda-approved regulatory

"an FDA-approved menin inhibitor"

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

menin inhibitor medical

"an FDA-approved menin inhibitor"

A menin inhibitor is a type of experimental drug that blocks the action of a protein called menin, which some cancers use to keep growing. Think of it as flipping off a switch that cancer cells rely on to survive; by doing so, these drugs can slow or stop tumor growth. Investors watch menin inhibitors because clinical trial results, regulatory approvals, and market demand determine whether they become valuable cancer treatments and potential revenue drivers.

monoclonal antibody medical

"an FDA-approved monoclonal antibody"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

csf-1 receptor medical

"blocks the colony stimulating factor 1 (CSF-1) receptor"

A cell-surface protein found mainly on certain immune cells that acts like a lock for signaling molecules such as colony-stimulating factor 1; when those molecules bind, the receptor tells the cell to grow, move or change behavior. As a biological control point in inflammation, tissue repair and some cancers, it is a common drug target; investors watch drug candidates and clinical results involving the receptor because they can affect the commercial and regulatory prospects of biotech companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2026 financial results and provide a business update on Monday, November 2, 2026.

In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, November 2, 2026.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:

Conference ID: Syndax3Q26
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast: https://sndx-3q26.open-exchange.net/

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G